Evolus Inc. (EOLS) stock plummeted 5.26% in pre-market trading on Wednesday, despite the company reporting strong Q4 and full-year 2024 financial results that exceeded expectations. The selling pressure likely stems from near-term costs associated with launching the company's new hyaluronic acid filler products.
For the fourth quarter, Evolus delivered global net revenue of $79 million, up 30% year-over-year, driven by continued strong growth of its Jeuveau neurotoxin product line. Evolus achieved non-GAAP operating profitability of $6.7 million in Q4, a significant milestone marking its first-ever quarterly profit.
Full-year 2024 revenue grew 32% to $266.3 million, at the high end of the company's guidance range. Evolus also reported full-year non-GAAP operating profitability, one year ahead of its stated goal. Its neurotoxin product captured around 14% market share in the US by the end of 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.